ANTERIS

DurAVR™ built with ADAPT® technology

Creating the world's most durable valve

www.anteristech.com | Follow us @anteristech

ADAPT for life

The TAVR market is growing significantly



By 2025, Global Aortic Valve Replacement to reach

$8B USD*

TAVR is expected to be 62% of procedure volume and 87% of market revenue.



*Includes Tier 1 markets (US,EU) and China; data on file

DurAVR™
A unique 3D single-piece Aortic Valve Replacement



DurAVR™ Designed to Last Longer(3) and Work Better(4,5)

DurAVR™ (an ADAPT® product)



Lasts Longer (3) → **Durability = full function over time**

(a)+(b) =

Works Better → **Better hemodynamics = Better outcomes**

(a) **No calcification**

(b) **Less mechanical stress**

Lower mean gradient*

Larger EOA's*

ADAPT®Tissue Science

DurAVR™ *3D Valve Design*

No DNA(1)
Most extensive (2) long- term data

Unique 3D single-piece valve
Zero leaflet wear and no diminished EOA at 12 years(3)

	△P (mmHg)	EOA (cm^2)
Normal	**4.0-5.0**	**3.5-4.00**
DurAVR	**3.86-5.34**	**3.04-3.28**
Corevalve(4)	7.76-10.27	1.44-1.66
Sapien(5)	11.66	1.35

1) Neethling et al data on file, 2) Neethling et al data on file, multiple publications,3) Neethling et al data on file
4) Midha et. al. 2016 JACC. 9 (15): 1618-28 5) * Hahn et. al. 2019 JACC. 12 (1): 25-34

ADAPT® TISSUE SCIENCE

First and only anti-calcification treatment demonstrating **zero** calcification in humans beyond 10 years

ADAPT® is widely studied and has been used in over 20,000 patients worldwide

- ✓ >20,000 implants in young patients with congenital heart disease
- ✓ 10-year clinical data with no calcification in pediatric patients
- ✓ Largest series is 500 patients

Publications include manuscripts, abstracts and posters

DurAVR™ shows zero wear in accelerated testing equivalent to 12 years

ACCELERATED WEAR TESTING

Anteris Valve shows no wear at 550 **million cycles**

Day 1 | **200 million** | **500 million**

Competitor Valves demonstrate wear and may breakdown at 250 million cycles

SHEEP CALCIFICATION MODEL

Well Anchored Sutures | **Supple Cusps** | **Clean Margins (Annulus)**



Valves implanted in juvenile sheep and assessed at 6 months:

- ADAPT® aortic valves show no calcification

DurAVR™ promises best in class hemodynamics

Design Option	Inner Diameter of Annulus or Surgical Valve(mm)	ΔP_{mean} (mmHg)	EOA (cm^2)
 DurAVR™ (25MM)	23	4.89	**3.07**
	21	5.17	**3.04**
 DurAVR™ (25 MM)	23	5.34	**3.26**
	21	3.86	**3.28**
COREVALVE* (26MM)	21 (True ID of 23mm Perimount)	7.76 ± 0.14	1.66 ± 0.05
COREVALVE* (23MM)		10.27 ± 0.18	1.44 ± 0.05
SAPIEN * (23MM)		11.66 ± 0.22	1.35 ± 0.02

SUPERIOR HEMODYNAMICS OF $\Delta P_{mean} \leq 6$ mmHg and EOA ≥ 2.9 cm^2

* Midha et. al. 2016 JACC. 9 (15): 1618-28

DurAVR™ First in Human study patient #1

"I have not seen these kind of results with commercially available valves" - Prof Bart Meuris

	Patients with other surgical valves* (N>1400)	DurAVR™ Patient 1
Peak Gradient mmHg	23	**11**
Mean Gradient mmHg	11	**5**
EOA cm^2	1.9	**2.9**

Post Operative Trans Esophageal Echo (TEE) of DurAVR™ Heart Valve

* Average of 1400 patients implanted with commercially available surgical valves at Leuven University Hospitals

DurAVR™ Designed to Last Longer(3) and Work Better(4,5)

DurAVR™ (an ADAPT® product)



Lasts Longer (3) → **Durability = full function over time**

Works Better → **Better hemodynamics = Better outcomes**

(a)+(b) =

(a) **No calcification**

(b) **Less mechanical stress**

Lower mean gradient*

Larger EOA's*

ADAPT®Tissue Science

DurAVR™ *3D Valve Design*

No DNA(1)
Most extensive (2) long- term data

Unique 3D single-piece valve
Zero leaflet wear and no diminished EOA at 12 years(3)

	△P (mmHg)	EOA (cm^2)
Normal	**4.0-5.0**	**3.5-4.00**
DurAVR	**3.86-5.34**	**3.04-3.28**
Corevalve(4)	7.76-10.27	1.44-1.66
Sapien(5)	11.66	1.35

1) Neethling et al data on file, 2) Neethling et al data on file, multiple publications,3) Neethling et al data on file
4) Midha et. al. 2016 JACC. 9 (15): 1618-28 5) * Hahn et. al. 2019 JACC. 12 (1): 25-34

Developing the world's most durable heart valve

The right science

- ADAPT® anti-calcification treatment is proven over 10 years in humans, with zero calcification in published studies.
- Zero DNA
- Zero residual glutaraldehyde

The right design

- The DurAVR™ 3D single-piece valve is proven to have less wear at the leaflets than conventional valves.
- Current tests suggest superior hemodynamic profile based on design benefits
- Significantly less sutures to manufacture than conventional valves

The right time

- The FDA approved the use of TAVR in "low risk" (younger) patients in 2019. Replacement valves need to last longer.